http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Sun, 31 May 2026 19:59:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Press+Releases/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. http://www.streetinsider.com/Globe+Newswire/BriaCell+Therapeutics+Announces+Pricing+of+Offering/26577514.html Sun, 31 May 2026 19:59:00 -0400 A.19657706 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.36250936 http://www.streetinsider.com/Press+Releases/BriaCell+Expands+Pipeline+to+Include+an+Ovarian+Cancer+Immunotherapy+Candidate%2C+Bria-OVA%2B%E2%84%A2/26499453.html <ul type="disc"><li style="text-align:justify;"><strong><em>BriaCell expands push in women’s health, building on Phase 2 success in advanced metastatic breast cancer</em></strong></li><li style="text-align:justify;"><strong><em>Bria-OVA+, BriaCell’s next generation personalized immunotherapy candidate for ovarian cancer, is designed with additional immune-stimulating components to support enhanced anti-tumor activity </em></strong></li><li style="text-align:justify;"><strong><em>Ovarian cancer remains the deadliest gynecologic cancer with over 12,000 women expected to die from the disease in 2026 in the U.S.</em></strong><br/></li></ul> <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, http://www.streetinsider.com/Press+Releases/BriaCell+Expands+Pipeline+to+Include+an+Ovarian+Cancer+Immunotherapy+Candidate%2C+Bria-OVA%2B%E2%84%A2/26499453.html Fri, 15 May 2026 07:30:00 -0400 A.09642568 A.11386304 A.60001765 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20363532 O.20371933 O.20738543 http://www.streetinsider.com/Press+Releases/BriaCell+Expands+Pipeline+to+Include+an+Ovarian+Cancer+Immunotherapy+Candidate%2C+Bria-OVA%2B%E2%84%A2/26499453.html <ul type="disc"><li style="text-align:justify;"><strong><em>BriaCell expands push in women’s health, building on Phase 2 success in advanced metastatic breast cancer</em></strong></li><li style="text-align:justify;"><strong><em>Bria-OVA+, BriaCell’s next generation personalized immunotherapy candidate for ovarian cancer, is designed with additional immune-stimulating components to support enhanced anti-tumor activity </em></strong></li><li style="text-align:justify;"><strong><em>Ovarian cancer remains the deadliest gynecologic cancer with over 12,000 women expected to die from the disease in 2026 in the U.S.</em></strong><br/></li></ul> <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, http://www.streetinsider.com/Press+Releases/BriaCell+Expands+Pipeline+to+Include+an+Ovarian+Cancer+Immunotherapy+Candidate%2C+Bria-OVA%2B%E2%84%A2/26499453.html Fri, 15 May 2026 07:30:00 -0400 A.09642568 A.11386304 A.60001765 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20363532 O.20371933 O.20738543 http://www.streetinsider.com/Press+Releases/BriaCell+Expands+Pipeline+to+Include+an+Ovarian+Cancer+Immunotherapy+Candidate%2C+Bria-OVA%2B%E2%84%A2/26499453.html <ul type="disc"><li style="text-align:justify;"><strong><em>BriaCell expands push in women’s health, building on Phase 2 success in advanced metastatic breast cancer</em></strong></li><li style="text-align:justify;"><strong><em>Bria-OVA+, BriaCell’s next generation personalized immunotherapy candidate for ovarian cancer, is designed with additional immune-stimulating components to support enhanced anti-tumor activity </em></strong></li><li style="text-align:justify;"><strong><em>Ovarian cancer remains the deadliest gynecologic cancer with over 12,000 women expected to die from the disease in 2026 in the U.S.</em></strong><br/></li></ul> <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, http://www.streetinsider.com/Press+Releases/BriaCell+Expands+Pipeline+to+Include+an+Ovarian+Cancer+Immunotherapy+Candidate%2C+Bria-OVA%2B%E2%84%A2/26499453.html Fri, 15 May 2026 07:30:00 -0400 A.09642568 A.11386304 A.60001765 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20363532 O.20371933 O.20738543 http://www.streetinsider.com/Press+Releases/BriaCell+Expands+Pipeline+to+Include+an+Ovarian+Cancer+Immunotherapy+Candidate%2C+Bria-OVA%2B%E2%84%A2/26499453.html <ul type="disc"><li style="text-align:justify;"><strong><em>BriaCell expands push in women’s health, building on Phase 2 success in advanced metastatic breast cancer</em></strong></li><li style="text-align:justify;"><strong><em>Bria-OVA+, BriaCell’s next generation personalized immunotherapy candidate for ovarian cancer, is designed with additional immune-stimulating components to support enhanced anti-tumor activity </em></strong></li><li style="text-align:justify;"><strong><em>Ovarian cancer remains the deadliest gynecologic cancer with over 12,000 women expected to die from the disease in 2026 in the U.S.</em></strong><br/></li></ul> <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, http://www.streetinsider.com/Press+Releases/BriaCell+Expands+Pipeline+to+Include+an+Ovarian+Cancer+Immunotherapy+Candidate%2C+Bria-OVA%2B%E2%84%A2/26499453.html Fri, 15 May 2026 07:30:00 -0400 A.09642568 A.11386304 A.60001765 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20363532 O.20371933 O.20738543 http://www.streetinsider.com/Press+Releases/BriaCell+Expands+Pipeline+to+Include+an+Ovarian+Cancer+Immunotherapy+Candidate%2C+Bria-OVA%2B%E2%84%A2/26499453.html <ul type="disc"><li style="text-align:justify;"><strong><em>BriaCell expands push in women’s health, building on Phase 2 success in advanced metastatic breast cancer</em></strong></li><li style="text-align:justify;"><strong><em>Bria-OVA+, BriaCell’s next generation personalized immunotherapy candidate for ovarian cancer, is designed with additional immune-stimulating components to support enhanced anti-tumor activity </em></strong></li><li style="text-align:justify;"><strong><em>Ovarian cancer remains the deadliest gynecologic cancer with over 12,000 women expected to die from the disease in 2026 in the U.S.</em></strong><br/></li></ul> <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, http://www.streetinsider.com/Press+Releases/BriaCell+Expands+Pipeline+to+Include+an+Ovarian+Cancer+Immunotherapy+Candidate%2C+Bria-OVA%2B%E2%84%A2/26499453.html Fri, 15 May 2026 07:30:00 -0400 A.09642568 A.11386304 A.60001765 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20363532 O.20371933 O.20738543 http://www.streetinsider.com/Press+Releases/BriaCell+Expands+Pipeline+to+Include+an+Ovarian+Cancer+Immunotherapy+Candidate%2C+Bria-OVA%2B%E2%84%A2/26499453.html <ul type="disc"><li style="text-align:justify;"><strong><em>BriaCell expands push in women’s health, building on Phase 2 success in advanced metastatic breast cancer</em></strong></li><li style="text-align:justify;"><strong><em>Bria-OVA+, BriaCell’s next generation personalized immunotherapy candidate for ovarian cancer, is designed with additional immune-stimulating components to support enhanced anti-tumor activity </em></strong></li><li style="text-align:justify;"><strong><em>Ovarian cancer remains the deadliest gynecologic cancer with over 12,000 women expected to die from the disease in 2026 in the U.S.</em></strong><br/></li></ul> <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, http://www.streetinsider.com/Press+Releases/BriaCell+Expands+Pipeline+to+Include+an+Ovarian+Cancer+Immunotherapy+Candidate%2C+Bria-OVA%2B%E2%84%A2/26499453.html Fri, 15 May 2026 07:30:00 -0400 A.09642568 A.11386304 A.60001765 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20363532 O.20371933 O.20738543 http://www.streetinsider.com/Press+Releases/BriaCell+Expands+Pipeline+to+Include+an+Ovarian+Cancer+Immunotherapy+Candidate%2C+Bria-OVA%2B%E2%84%A2/26499453.html <ul type="disc"><li style="text-align:justify;"><strong><em>BriaCell expands push in women’s health, building on Phase 2 success in advanced metastatic breast cancer</em></strong></li><li style="text-align:justify;"><strong><em>Bria-OVA+, BriaCell’s next generation personalized immunotherapy candidate for ovarian cancer, is designed with additional immune-stimulating components to support enhanced anti-tumor activity </em></strong></li><li style="text-align:justify;"><strong><em>Ovarian cancer remains the deadliest gynecologic cancer with over 12,000 women expected to die from the disease in 2026 in the U.S.</em></strong><br/></li></ul> <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, http://www.streetinsider.com/Press+Releases/BriaCell+Expands+Pipeline+to+Include+an+Ovarian+Cancer+Immunotherapy+Candidate%2C+Bria-OVA%2B%E2%84%A2/26499453.html Fri, 15 May 2026 07:30:00 -0400 A.09642568 A.11386304 A.60001765 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20363532 O.20371933 O.20738543 http://www.streetinsider.com/Press+Releases/BriaCell+Expands+Pipeline+to+Include+an+Ovarian+Cancer+Immunotherapy+Candidate%2C+Bria-OVA%2B%E2%84%A2/26499453.html <ul type="disc"><li style="text-align:justify;"><strong><em>BriaCell expands push in women’s health, building on Phase 2 success in advanced metastatic breast cancer</em></strong></li><li style="text-align:justify;"><strong><em>Bria-OVA+, BriaCell’s next generation personalized immunotherapy candidate for ovarian cancer, is designed with additional immune-stimulating components to support enhanced anti-tumor activity </em></strong></li><li style="text-align:justify;"><strong><em>Ovarian cancer remains the deadliest gynecologic cancer with over 12,000 women expected to die from the disease in 2026 in the U.S.</em></strong><br/></li></ul> <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, http://www.streetinsider.com/Press+Releases/BriaCell+Expands+Pipeline+to+Include+an+Ovarian+Cancer+Immunotherapy+Candidate%2C+Bria-OVA%2B%E2%84%A2/26499453.html Fri, 15 May 2026 07:30:00 -0400 A.09642568 A.11386304 A.60001765 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20363532 O.20371933 O.20738543 http://www.streetinsider.com/Press+Releases/BriaCell+Expands+Pipeline+to+Include+an+Ovarian+Cancer+Immunotherapy+Candidate%2C+Bria-OVA%2B%E2%84%A2/26499453.html <ul type="disc"><li style="text-align:justify;"><strong><em>BriaCell expands push in women’s health, building on Phase 2 success in advanced metastatic breast cancer</em></strong></li><li style="text-align:justify;"><strong><em>Bria-OVA+, BriaCell’s next generation personalized immunotherapy candidate for ovarian cancer, is designed with additional immune-stimulating components to support enhanced anti-tumor activity </em></strong></li><li style="text-align:justify;"><strong><em>Ovarian cancer remains the deadliest gynecologic cancer with over 12,000 women expected to die from the disease in 2026 in the U.S.</em></strong><br/></li></ul> <p align="justify">PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, http://www.streetinsider.com/Press+Releases/BriaCell+Expands+Pipeline+to+Include+an+Ovarian+Cancer+Immunotherapy+Candidate%2C+Bria-OVA%2B%E2%84%A2/26499453.html Fri, 15 May 2026 07:30:00 -0400 A.09642568 A.11386304 A.60001765 BCT BCTX BCTXL BCTXW BCTXZ O.04468025 O.20363532 O.20371933 O.20738543